Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852646 | 0.76 | DRD2 (0.32) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1448551 | 0.73 | — | — | |
| SCHEMBL19952426 | 0.71 | DRD2 (0.34) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL18096327 | 0.70 | BACE1 (0.31) | — | |
| SCHEMBL22254593 | 0.70 | DRD2 (0.33) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL23364789 | 0.69 | BACE1 (0.34) | DRD2DRD3 | |
| SCHEMBL25136394 | 0.69 | — | — | |
| SCHEMBL17256472 | 0.69 | BACE1 (0.34) | — | |
| SCHEMBL31570424 | 0.69 | BACE1 (0.30) | — | |
| SCHEMBL31263221 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4434990-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| EP-3814357-B1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11407753-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210238186-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS HD, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3814357-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-111065626-A | Compounds for the treatment of huntington's chorea | PTC医疗公司 | 2020-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 103/4885GLA 989/4885KMT2A 2554/4885 |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | HTT, HYPK, FH | SMN1; SMN2 186/4885GLA 168/4885KMT2A 1133/4885 |
| US-20210238186-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | SMN1; SMN2 186/4885GLA 168/4885KMT2A 1133/4885 |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | SMN1; SMN2 104/4885GLA 87/4885KMT2A 1146/4885 |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HCN3, TRPV1 | SMN1; SMN2 1309/4885GLA 2090/4885KMT2A 1843/4885 |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | SMN1; SMN2 104/4885GLA 87/4885KMT2A 1146/4885 |
| US-11407753-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | SMN1; SMN2 104/4885GLA 87/4885KMT2A 1146/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | SMN1; SMN2 104/4885GLA 87/4885KMT2A 1146/4885 |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | SMN1; SMN2 243/4885GLA 604/4885KMT2A 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.